Cardiovascular diseases in patients receiving small molecules with anti-vascular endothelial growth factor activity: A meta-analysis of approximately 29,000 cancer patients
Restricted accessResearch articleFirst published online March, 2018
Cardiovascular diseases in patients receiving small molecules with anti-vascular endothelial growth factor activity: A meta-analysis of approximately 29,000 cancer patients
Targeted therapy with tyrosine kinase inhibitors with anti-vascular endothelial growth factor activity improves survival of cancer patients. Cardiovascular complications are critical and it is unknown whether these require specific treatment strategies. We aimed to clarify the associated risk of cardiovascular adverse events in patients treated with tyrosine kinase inhibitors.
Design
The design of this study was a meta-analysis of randomised controlled trials.
Methods
We searched PubMed, Cochrane, EMBASE and Web of Science databases for randomised controlled trials published until January 2017 that assessed patients with different types of cancer treated with or without tyrosine kinase inhibitors in addition to standard chemotherapy.
Results
A total of 29,252 patients from 71 randomised controlled trials were included. Tyrosine kinase inhibitor treatment was associated with a higher cardiac ischaemia relative risk (relative risk = 1.69; 95% confidence interval: 1.12–2.57; p = 0.01), with the highest risks observed for sorafenib and patients with renal cancer. Risk of thrombocytopaenia (relative risk = 2.2; 95% confidence interval: 1.73–2.79; p < 0.001) was highest for regorafenib and patients with breast cancer. Left ventricular systolic dysfunction was increased after tyrosine kinase inhibitor therapy (relative risk = 2.53; 95% confidence interval:1.79 – 3.57; p < 0.001), with the highest risks reported for sunitinib and hepatocellular cancer. QT corrected interval prolongation (relative risk = 6.25; 95% confidence interval: 3.44–11.38; p < 0.001) and arterial hypertension (relative risk = 3.78; 95% confidence interval: 3.15-4.54; p < 0.001) were reported. The relative risks of arterial adverse events, cerebral ischaemia, venous adverse events and pulmonary embolism were similar across groups.
Conclusion
Tyrosine kinase inhibitors increase the risk of severe cardiovascular and particularly thrombotic adverse events. Specific treatment regimens when prescribing tyrosine kinase inhibitor therapies appear desirable.
SiegelRLMillerKDJemalA. Cancer statistics, 2016. CA Cancer J Clin2016; 66: 7–30.
2.
ZamoranoJLLancellottiPRodriguez MunozDet al.2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J2016; 37: 2768–2801.
3.
JaysonGCKerbelREllisLMet al.Antiangiogenic therapy in oncology: Current status and future directions. Lancet2016; 388: 518–529.
4.
LiWCroceKSteensmaDPet al.Vascular and metabolic implications of novel targeted cancer therapies: Focus on kinase inhibitors. J Am Coll Cardiol2015; 66: 1160–1178.
5.
LiuBDingFLiuYet al.Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: A comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients. Oncotarget2016; 7: 67661–67673.
6.
ChoueiriTKSchutzFAJeYet al.Risk of arterial thromboembolic events with sunitinib and sorafenib: A systematic review and meta-analysis of clinical trials. J Clin Oncol2010; 28: 2280–2285.
7.
LiBTBarnesTAChanDLet al.The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials. Lung Cancer2016; 102: 21–27.
8.
WenTXiaoHLuoCet al.Efficacy of sequential therapies with sorafenib-sunitinib versus sunitinib-sorafenib in metastatic renal cell carcinoma: A systematic review and meta-analysis. Oncotarget2017; 8(12): 20441–20451.
9.
YuJZhangYLeungLHet al.Efficacy and safety of angiogenesis inhibitors in advanced gastric cancer: A systematic review and meta-analysis. J Hematol Oncol2016; 9: 111–111.
10.
ZhangDZhangXZhaoC. Risk of venous and arterial thromboembolic events associated with anti-VEGF agents in advanced non-small-cell lung cancer: A meta-analysis and systematic review. Onco Targets Ther2016; 9: 3695–3704.
11.
Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from http://handbook.cochrane.org.
12.
LiberatiAAltmanDGTetzlaffJet al.The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration. BMJ2009; 339: b2700–b2700.
13.
TotzeckMMincuRIRassafT. Cardiovascular adverse events in patients with cancer treated with bevacizumab: A meta-analysis of more than 20 000 patients. J Am Heart Assoc2017; 6(8): doi: 10.1161/JAHA.117.006278.
14.
Belani CP, Yamamoto N, Bondarenko IM, et al. Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer. BMC Cancer. 2014; 14: 290. doi: 10.1186/1471-2407-14-290.
15.
IokaTOkusakaTOhkawaSet al.Efficacy and safety of axitinib in combination with gemcitabine in advanced pancreatic cancer: Subgroup analyses by region, including Japan, from the global randomized Phase III trial. Jpn J Clin Oncol2015; 45: 439–448.
16.
KangYYauTParkJet al.Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma. Ann Oncol2015; 26: 2457–2463.
17.
KindlerHIokaTRichelDet al.Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: A double-blind randomised phase 3 study. Lancet Oncol2011; 12: 256–262.
18.
RiniBMelicharBUedaTet al.Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: A randomised double-blind phase 2 trial. Lancet Oncol2013; 14: 1233–1242.
19.
RugoHStopeckAJoyAet al.Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer. J Clin Oncol2011; 29: 2459–2465.
20.
SpanoJChodkiewiczCMaurelJet al.Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: An open-label randomised phase II study. Lancet2008; 371: 2101–2108.
21.
SchlumbergerMTaharaMWirthLJet al.Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med2015; 372: 621–630.
22.
MotzerRJHutsonTEGlenHet al.Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: A randomised, phase 2, open-label, multicentre trial. Lancet Oncol2015; 16: 1473–1482.
23.
du BoisAKristensenGRay-CoquardIet al.Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol2016; 17: 78–89.
24.
HannaNHKaiserRSullivanRNet al.Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial. Lung Cancer2016; 102: 65–73.
25.
LedermannJAHackshawAKayeSet al.Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. J Clin Oncol2011; 29: 3798–3804.
26.
ReckMKaiserRMellemgaardAet al.Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): A phase 3, double-blind, randomised controlled trial. Lancet Oncol2014; 15: 143–155.
27.
SternbergCNDavisIDMardiakJet al.Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial. J Clin Oncol2010; 28: 1061–1068.
28.
van der GraafWTBlayJYChawlaSPet al.Pazopanib for metastatic soft-tissue sarcoma (PALETTE): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet2012; 379: 1879–1886.
29.
MirOCropetCToulmondeMet al.Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): A randomised, multicentre, open-label phase 2 trial. Lancet Oncol2016; 17: 632–641.
30.
du BoisAFloquetAKimJWet al.Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol2014; 32: 3374–3382.
31.
O'BrienMEGaafarRHasanBet al.Maintenance pazopanib versus placebo in non-small cell lung cancer patients non-progressive after first line chemotherapy: A double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064). Eur J Cancer2015; 51: 1511–1528.
32.
PignataSLorussoDScambiaGet al.Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): A randomised, open-label, phase 2 trial. Lancet Oncol2015; 16: 561–568.
33.
DemetriGDReichardtPKangYKet al.Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet2013; 381: 295–302.
34.
GrotheyAVan CutsemESobreroAet al.Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet2013; 381: 303–312.
35.
PavlakisNSjoquistKMMartinAJet al.Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): A multinational placebo-controlled phase II trial. J Clin Oncol2016; 34: 2728–2735.
36.
BruixJQinSMerlePet al.Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet2017; 389: 56–66.
37.
MirOBrodowiczTItalianoAet al.Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): A randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol2016; 17: 1732–1742.
38.
LiJQinSXuRet al.Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol2015; 16: 619–629.
39.
Abou-AlfaGKJohnsonPKnoxJJet al.Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: A randomized trial. JAMA2010; 304: 2154–2160.
40.
BaselgaJCostaFGomezHet al.A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): Study protocol for a randomized controlled trial. Trials2013; 14: 228–228.
41.
BroseMSNuttingCMJarzabBet al.Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: A randomised, double-blind, phase 3 trial. Lancet2014; 384: 319–328.
42.
BruixJTakayamaTMazzaferroVet al.Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): A phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol2015; 16: 1344–1354.
43.
ChengALKangYKChenZet al.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol2009; 10: 25–34.
44.
EscudierBEisenTStadlerWMet al.Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol2009; 27: 3312–338.
45.
FlahertyKTLeeSJZhaoFet al.Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. J Clin Oncol2013; 31: 373–379.
46.
GoncalvesAGilabertMFrancoisEet al.BAYPAN study: A double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer. Ann Oncol2012; 23: 2799–2805.
47.
GradisharWJKaklamaniVSahooTPet al.A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer. Eur J Cancer2013; 49: 312–322.
48.
HauschildAAgarwalaSSTrefzerUet al.Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol2009; 27: 2823–2830.
49.
HainsworthJDThompsonDSBismayerJAet al.Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: A randomized phase II study of the Sarah Cannon Research Institute. Cancer Med2015; 4: 673–681.
50.
HerzogTJScambiaGKimBGet al.A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma. Gynecol Oncol2013; 130: 25–30.
51.
KregeSRexerHvom DorpFet al.Prospective randomized double-blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer: SUSE (AUO-AB 31/05). BJU Int2014; 113: 429–436.
52.
LlovetJMRicciSMazzaferroVet al.Sorafenib in advanced hepatocellular carcinoma. N Engl J Med2008; 359: 378–390.
53.
McDermottDFSosmanJAGonzalezRet al.Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: A report from the 11715 Study Group. J Clin Oncol2008; 26: 2178–2185.
54.
NegrierSJagerEPortaCet al.Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET. Med Oncol2010; 27: 899–906.
55.
Paz-AresLGBiesmaBHeigenerDet al.Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer. J Clin Oncol2012; 30: 3084–3092.
56.
ScagliottiGNovelloSvon PawelJet al.Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol2010; 28: 1835–1842.
57.
SchwartzbergLSTauerKWHermannRCet al.Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab. Clin Cancer Res2013; 19: 2745–2754.
58.
TaberneroJGarcia-CarboneroRCassidyJet al.Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: The RESPECT trial. Clin Cancer Res2013; 19: 2541–2550.
59.
HaasNBManolaJUzzoRGet al.Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): A double-blind, placebo-controlled, randomised, phase 3 trial. Lancet2016; 387: 2008–2016.
60.
BerghJBondarenkoIMLichinitserMRet al.First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: Results of a prospective, randomized phase III study. J Clin Oncol2012; 30: 921–929.
61.
CarratoASwieboda-SadlejAStaszewska-SkurczynskaMet al.Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: A randomized, phase III trial. J Clin Oncol2013; 31: 1341–1347.
62.
CrownJPDierasVStaroslawskaEet al.Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. J Clin Oncol2013; 31: 2870–2878.
63.
DemetriGDvan OosteromATGarrettCRet al.Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet2006; 368: 1329–1338.
64.
HeistRSWangXHodgsonLet al.CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer. J Thorac Oncol2014; 9: 214–221.
65.
MichaelsonMDOudardSOuYCet al.Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer. J Clin Oncol2014; 32: 76–82.
66.
MoehlerMGepfner-TumaIMadererAet al.Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: A randomized, placebo-controlled phase II AIO trial with serum biomarker program. BMC Cancer2016; 16: 699–699.
67.
RaymondEDahanLRaoulJLet al.Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med2011; 364: 501–513.
68.
ReniMCeredaSMilellaMet al.Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: A phase II randomised trial. Eur J Cancer2013; 49: 3609–3615.
69.
WildiersHFontaineCVuylstekePet al.Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer. Breast Cancer Res Treat2010; 123: 463–469.
70.
YiJHLeeJLeeJet al.Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. Br J Cancer2012; 106: 1469–1474.
71.
MotzerRJHutsonTETomczakPet al.Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol2009; 27: 3584–3590.
72.
AisnerJManolaJBDakhilSRet al.Vandetanib plus chemotherapy for induction followed by vandetanib or placebo as maintenance for patients with advanced non-small-cell lung cancer: A randomized phase 2 PrECOG study (PrE0501). J Thorac Oncol2013; 8: 1075–1083.
73.
AhnJSLeeKHSunJMet al.A randomized, phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapy. Lung Cancer2013; 82: 455–460.
74.
ArnoldAMSeymourLSmylieMet al.Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. J Clin Oncol2007; 25: 4278–4284.
75.
de BoerRHArrietaOYangCHet al.Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: A randomized, double-blind phase III trial. J Clin Oncol2011; 29: 1067–1074.
76.
ColemanRLMoonJSoodAKet al.Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904. Eur J Cancer2014; 50: 1638–1648.
77.
HerbstRSSunYEberhardtWEet al.Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): A double-blind, randomised, phase 3 trial. Lancet Oncol2010; 11: 619–626.
78.
HeymachJVJohnsonBEPragerDet al.Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol2007; 25: 4270–4277.
79.
HeymachJVPaz-AresLDe BraudFet al.Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol2008; 26: 5407–5415.
80.
HortiJWidmarkAStenzlAet al.A randomized, double-blind, placebo-controlled phase II study of vandetanib plus docetaxel/prednisolone in patients with hormone-refractory prostate cancer. Cancer Biother Radiopharm2009; 24: 175–180.
81.
HsuCYangTSHuoTIet al.Vandetanib in patients with inoperable hepatocellular carcinoma: A phase II, randomized, double-blind, placebo-controlled study. J Hepatol2012; 56: 1097–1103.
82.
LeboulleuxSBastholtLKrauseTet al.Vandetanib in locally advanced or metastatic differentiated thyroid cancer: A randomised, double-blind, phase 2 trial. Lancet Oncol2012; 13: 897–905.
83.
LeeJSHirshVParkKet al.Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: A randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol2012; 30: 1114–1121.
84.
SanbornREPatelJDMastersGAet al.A randomized, double-blind, phase 2 trial of platinum therapy plus etoposide with or without concurrent vandetanib (ZD6474) in patients with previously untreated extensive-stage small cell lung cancer: Hoosier Cancer Research Network LUN06-113. Cancer2017; 123: 303–311.
85.
WellsSAJrRobinsonBGGagelRFet al.Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: A randomized, double-blind phase III trial. J Clin Oncol2012; 30: 134–141.
86.
KangYKYauTParkJWet al.Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma. Ann Oncol2015; 26: 2457–2463.
87.
BelaniCPYamamotoNBondarenkoIMet al.Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer. BMC Cancer2014; 14: 290–290.
88.
WildiersHFontaineCVuylstekePet al.Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer. Breast Cancer Res Treat2010; 123: 463–469.
89.
GrotheyAVan CutsemESobreroAet al.Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet2013; 381: 303–312.
90.
HauschildAGutzmerRUgurelSet al.Sorafenib and pegylated interferon alpha 2b in advanced metastatic melanoma: A multicenter phase II DECOG trial. Melanoma Res2010; 20: e33–e33.
VerheulHMPinedoHM. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer2007; 7: 475–485.
93.
SchraermeyerUJulienS. Formation of immune complexes and thrombotic microangiopathy after intravitreal injection of bevacizumab in the primate eye. Graefes Arch Clin Exp Ophthalmol2012; 250: 1303–1313.
94.
BellingerAMArteagaCLForceTet al.Cardio-oncology: How new targeted cancer therapies and precision medicine can inform cardiovascular discovery. Circulation2015; 132: 2248–2258.
95.
QiWXShenZTangLNet al.Risk of arterial thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: An up-to-date meta-analysis. Crit Rev Oncol Hematol2014; 92: 71–82.
96.
Abdel-QadirHEthierJLLeeDSet al.Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis. Cancer Treat Rev2017; 53: 120–127.
97.
RanpuraVHapaniSChuangJet al.Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis of randomized controlled trials. Acta Oncol2010; 49: 287–297.
98.
FunakoshiTLatifAGalskyMD. Safety and efficacy of addition of VEGFR and EGFR-family oral small-molecule tyrosine kinase inhibitors to cytotoxic chemotherapy in solid cancers: A systematic review and meta-analysis of randomized controlled trials. Cancer Treat Rev2014; 40: 636–647.
99.
SchutzFAJeYRichardsCJet al.Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors. J Clin Oncol2012; 30: 871–877.
100.
Abdel-RahmanOElhalawaniH. Risk of fatal pulmonary events in patients with advanced non-small-cell lung cancer treated with EGF receptor tyrosine kinase inhibitors: A comparative meta-analysis. Future Oncol2015; 11: 1109–1122.
101.
MasseyPROkmanJSWilkersonJet al.Tyrosine kinase inhibitors directed against the vascular endothelial growth factor receptor (VEGFR) have distinct cutaneous toxicity profiles: A meta-analysis and review of the literature. Support Care Cancer2015; 23: 1827–1835.
102.
TeoYLHoHKChanA. Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients: A meta-analysis. Cancer Treat Rev2013; 39: 199–206.
Klein HesselinkENSteenvoordenDKapiteijnEet al.Therapy of endocrine disease: Response and toxicity of small-molecule tyrosine kinase inhibitors in patients with thyroid carcinoma: A systematic review and meta-analysis. Eur J Endocrinol2015; 172: R215–R225.
105.
LymanGHKhoranaAAKudererNMet al.Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol2013; 31: 2189–2204.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
